Boston Scientific (BSX) Status Update summary

Market overview and growth

• Cardiology-served markets are valued at $40 billion, projected to grow at 8% CAGR through 2027.

• Interventional Cardiology Therapies, Structural Heart Valves, and Coronary Therapies are key segments, each with high single- or double-digit growth rates.

• 2024 served markets for Interventional Cardiology estimated at $15B, also growing 8% through 2027.

• Year-to-date growth: U.S. at 27%, international at 18%, with global net sales up 23%.

• Diversification into high-growth areas like mechanical circulatory support is part of the long-range plan.

Financial performance and sales growth

• Cardiology achieved 23% global net sales growth year-to-date 2024, with 27% growth in the U.S. and 18% internationally.

• Electrophysiology saw 126% operational growth, Watchman 19%, and Interventional Cardiology Therapies 12% for the first nine months of 2024.

• All revenue growth rates are operational and exclude foreign currency impacts unless noted.

Product launches and clinical advancements

• AGENT Drug-Coated Balloon received FDA approval and launched in the U.S.; AVVIGO+ Guidance System launched in Canada and India.

• FARAVIEW mapping software and FARAWAVE NAV mapping/ablation catheter received PMA supplemental approval and went live in multiple accounts.

• ACURATE Prime platform launched in Europe after CE Mark approval, offering enhanced clinical performance and expanded patient eligibility.

• AVVIGO+ platform, featuring advanced AI capabilities, is driving increased IVUS usage and market share above 50%, launched in 45+ countries.

• WATCHMAN TruSteer and FARAPULSE Pulsed Field Ablation System received FDA approvals and launched in the U.S.